rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ADXN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Thursday's Intraday Session
      Nov 12BenzingaADXN
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Nov 12BenzingaADXN
      Addex Spin-out Neurosterix Closes $105 Million Series B Financing
      Nov 11Yahoo FinanceADXN
      Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
      Oct 8Yahoo FinanceADXN
      Addex Therapeutics Announces Executive Management Changes
      Oct 1Yahoo FinanceADXN
      Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ...
      Oct 1Yahoo FinanceADXN
      Earnings call transcript: Addex Therapeutics falls on H1 2026 update and funding focus
      Sep 28Investing.comADXN
      Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Addex Therapeutics (NASDAQ:AD

      Addex Therapeutics (NASDAQ:ADXN) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

      Sep 28BenzingaADXN
      Earnings Scheduled For September 28, 2026
      Sep 28BenzingaADXNIVAKNDI
      Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
      Sep 28Yahoo FinanceADXN
      Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
      Sep 24Yahoo FinanceADXNINDV
      Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

      Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a

      Sep 24Yahoo FinanceADXN
      ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

      Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

      Aug 26BarchartADXN

      This is the newest page. Registered accounts read further back.